Resection of liver metastases from breast cancer
Background The oncologic benefit of resecting liver metastases in patients with breast cancer is unclear. This study was performed to identify predictors of survival after hepatectomy. Methods Between 1997 and 2010, 86 patients underwent resection of breast cancer liver metastases. Clinicopathologic...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , |
| Format: | article |
| Published: |
2012
|
| Online Access: | http://hdl.handle.net/10725/2649 http://dx.doi.org/10.1016/j.surg.2011.12.017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513459035570176 |
|---|---|
| author | Abbott, Daniel |
| author2 | Brouquet, Antoine Mittendorf, Elizabeth Andreou, Andreas Meric-Bernstam, Funda Valero, Vicente Green, Marjorie Kuerer, Henry Curley, Steven Vauthey, Jean-Nicolas Abdalla, Eddie Hunt, Kelly |
| author2_role | author author author author author author author author author author author |
| author_facet | Abbott, Daniel Brouquet, Antoine Mittendorf, Elizabeth Andreou, Andreas Meric-Bernstam, Funda Valero, Vicente Green, Marjorie Kuerer, Henry Curley, Steven Vauthey, Jean-Nicolas Abdalla, Eddie Hunt, Kelly |
| author_role | author |
| dc.creator.none.fl_str_mv | Abbott, Daniel Brouquet, Antoine Mittendorf, Elizabeth Andreou, Andreas Meric-Bernstam, Funda Valero, Vicente Green, Marjorie Kuerer, Henry Curley, Steven Vauthey, Jean-Nicolas Abdalla, Eddie Hunt, Kelly |
| dc.date.none.fl_str_mv | 2012 2015-11-20T10:09:11Z 2015-11-20T10:09:11Z 2015-11-20 |
| dc.identifier.none.fl_str_mv | 0039-6060 http://hdl.handle.net/10725/2649 http://dx.doi.org/10.1016/j.surg.2011.12.017 Abbott, D. E., Brouquet, A., Mittendorf, E. A., Andreou, A., Meric-Bernstam, F., Valero, V., ... & Vauthey, J. N. (2012). Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery, 151(5), 710-716. |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Surgery |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Resection of liver metastases from breast cancer Estrogen receptor status and response to chemotherapy before metastasectomy define outcome |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Background The oncologic benefit of resecting liver metastases in patients with breast cancer is unclear. This study was performed to identify predictors of survival after hepatectomy. Methods Between 1997 and 2010, 86 patients underwent resection of breast cancer liver metastases. Clinicopathologic characteristics of the primary breast neoplasm, timing of metastasis development, and treatment were recorded. Response to prehepatectomy chemotherapy was evaluated according to Response Criteria in Solid Tumors criteria, and the best response to chemotherapy during treatment and the response immediately before hepatectomy were noted. Univariate and multivariate analyses were performed to identify predictors of disease-free survival and overall survival. Results Fifty-nine patients (69%) had estrogen receptor– or progesterone receptor– positive primary breast neoplasms. Fifty-three patients (62%) had a solitary breast cancer liver metastasis, and 73 (85%) had breast cancer liver metastases ≤5 cm. Sixty-five patients (76%) received prehepatectomy hormonal and/or chemotherapy. Four patients (6%) had progressive disease as the best response, and 19 patients (30%) had progressive disease before hepatectomy (P < .001). Seventy percent of patients who received preoperative chemotherapy or hormonal therapy had either response or stable disease immediately before hepatectomy. No postoperative deaths were observed. At a 62-month median follow-up, the disease-free survival and overall survival were 14 and 57 months, respectively. On univariate analysis, estrogen receptor/progesterone receptor status of the primary breast neoplasm, best radiographic response, and preoperative radiographic response were associated with overall survival. On multivariate analysis, estrogen receptor–negative primary breast disease (P = .009; hazard ratio, 3.3; 95% confidence interval, 1.4–8.2) and preoperative progressive disease (P = .003; hazard ratio, 3.8; 95% confidence interval, 1.6–9.2) were associated with decreased overall survival. Conclusion Resection of breast cancer liver metastases in patients with estrogen receptor–positive disease that is responding to chemotherapy is associated with improved survival. The timing of operative intervention may be critical; resection before progression is associated with a better outcome. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_eb465f5a0af6ad2ec6c93cc4521ee7c1 |
| identifier_str_mv | 0039-6060 Abbott, D. E., Brouquet, A., Mittendorf, E. A., Andreou, A., Meric-Bernstam, F., Valero, V., ... & Vauthey, J. N. (2012). Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery, 151(5), 710-716. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/2649 |
| publishDate | 2012 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Resection of liver metastases from breast cancerEstrogen receptor status and response to chemotherapy before metastasectomy define outcomeAbbott, DanielBrouquet, AntoineMittendorf, ElizabethAndreou, AndreasMeric-Bernstam, FundaValero, VicenteGreen, MarjorieKuerer, HenryCurley, StevenVauthey, Jean-NicolasAbdalla, EddieHunt, KellyBackground The oncologic benefit of resecting liver metastases in patients with breast cancer is unclear. This study was performed to identify predictors of survival after hepatectomy. Methods Between 1997 and 2010, 86 patients underwent resection of breast cancer liver metastases. Clinicopathologic characteristics of the primary breast neoplasm, timing of metastasis development, and treatment were recorded. Response to prehepatectomy chemotherapy was evaluated according to Response Criteria in Solid Tumors criteria, and the best response to chemotherapy during treatment and the response immediately before hepatectomy were noted. Univariate and multivariate analyses were performed to identify predictors of disease-free survival and overall survival. Results Fifty-nine patients (69%) had estrogen receptor– or progesterone receptor– positive primary breast neoplasms. Fifty-three patients (62%) had a solitary breast cancer liver metastasis, and 73 (85%) had breast cancer liver metastases ≤5 cm. Sixty-five patients (76%) received prehepatectomy hormonal and/or chemotherapy. Four patients (6%) had progressive disease as the best response, and 19 patients (30%) had progressive disease before hepatectomy (P < .001). Seventy percent of patients who received preoperative chemotherapy or hormonal therapy had either response or stable disease immediately before hepatectomy. No postoperative deaths were observed. At a 62-month median follow-up, the disease-free survival and overall survival were 14 and 57 months, respectively. On univariate analysis, estrogen receptor/progesterone receptor status of the primary breast neoplasm, best radiographic response, and preoperative radiographic response were associated with overall survival. On multivariate analysis, estrogen receptor–negative primary breast disease (P = .009; hazard ratio, 3.3; 95% confidence interval, 1.4–8.2) and preoperative progressive disease (P = .003; hazard ratio, 3.8; 95% confidence interval, 1.6–9.2) were associated with decreased overall survival. Conclusion Resection of breast cancer liver metastases in patients with estrogen receptor–positive disease that is responding to chemotherapy is associated with improved survival. The timing of operative intervention may be critical; resection before progression is associated with a better outcome.PublishedN/A2015-11-20T10:09:11Z2015-11-20T10:09:11Z20122015-11-20Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0039-6060http://hdl.handle.net/10725/2649http://dx.doi.org/10.1016/j.surg.2011.12.017Abbott, D. E., Brouquet, A., Mittendorf, E. A., Andreou, A., Meric-Bernstam, F., Valero, V., ... & Vauthey, J. N. (2012). Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery, 151(5), 710-716.enSurgeryinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/26492019-02-26T10:55:17Z |
| spellingShingle | Resection of liver metastases from breast cancer Abbott, Daniel |
| status_str | publishedVersion |
| title | Resection of liver metastases from breast cancer |
| title_full | Resection of liver metastases from breast cancer |
| title_fullStr | Resection of liver metastases from breast cancer |
| title_full_unstemmed | Resection of liver metastases from breast cancer |
| title_short | Resection of liver metastases from breast cancer |
| title_sort | Resection of liver metastases from breast cancer |
| url | http://hdl.handle.net/10725/2649 http://dx.doi.org/10.1016/j.surg.2011.12.017 |